6-methyl-1,6-naphthyridinium cation | 772277-54-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-methyl-1,6-naphthyridinium cation
• 英文别名: mono-N-Methyl-1,6-naphthyridinium⁺；6-Methyl-1,6-naphthyridinium-Kation；6-Methyl-1,6-naphthyridinium；6-Methyl-1,6-naphthyridin-6-ium
• CAS: 772277-54-0
• 化学式: C₉H₉N₂
• 分子量: 145.184
• InChiKey: SDJRJYIVLXYOAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  16.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-methyl-1,6-naphthyridinium cation 在 sodium tetrahydroborate 作用下， 以 甲醇 、 水 为溶剂， 以68%的产率得到6-methyl-5,6,7,8-tetrahydro-[1,6]naphthyridine
  参考文献：
  名称：

  Antivertigo agents. II. Structure-activity relationships of 6-substituted 5,6,7,8-tetrahydro-1,6-naphthyridines.

  摘要：

  通过还原相应的 1，6-萘啶鎓盐，合成了一些 6-取代的 5，6，7，8-四氢-1，6-萘啶，它们被设计为 2-（2-甲基氨基乙基）吡啶的环状同系物。根据这些衍生物抑制猫自发性眼球震颤的能力，对其抗眩晕活性进行了评估。通过基于 6 位取代基亲油性（π）的回归分析，以及使用改进的忽略二原子重叠分子轨道法对相关化合物进行构象分析，研究了受试化合物的分子结构与其抗眩晕活性之间的关系。在这些化合物中，6-烯丙基和 6-环丙基甲基衍生物表现出极强的活性，同时大大降低了降压作用。

  DOI：

  10.1248/cpb.32.995
• 作为产物：
  描述：

  1,6-二氮萘 、 alkaline earth salt of/the/ methylsulfuric acid 以 乙腈 为溶剂， 生成 6-methyl-1,6-naphthyridinium cation
  参考文献：
  名称：

  Antivertigo agents. II. Structure-activity relationships of 6-substituted 5,6,7,8-tetrahydro-1,6-naphthyridines.

  摘要：

  通过还原相应的 1，6-萘啶鎓盐，合成了一些 6-取代的 5，6，7，8-四氢-1，6-萘啶，它们被设计为 2-（2-甲基氨基乙基）吡啶的环状同系物。根据这些衍生物抑制猫自发性眼球震颤的能力，对其抗眩晕活性进行了评估。通过基于 6 位取代基亲油性（π）的回归分析，以及使用改进的忽略二原子重叠分子轨道法对相关化合物进行构象分析，研究了受试化合物的分子结构与其抗眩晕活性之间的关系。在这些化合物中，6-烯丙基和 6-环丙基甲基衍生物表现出极强的活性，同时大大降低了降压作用。

  DOI：

  10.1248/cpb.32.995

文献信息

• PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS
  申请人：Relay Therapeutics, Inc.

  公开号：US20200172546A1

  公开（公告）日：2020-06-04

  The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure
• SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Relay Therapeutics, Inc.

  公开号：US20220315586A1

  公开（公告）日：2022-10-06

  The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
• Antivertigo agents. II. Structure-activity relationships of 6-substituted 5,6,7,8-tetrahydro-1,6-naphthyridines.
  作者：AKIRA SHIOZAWA、YUHICHIRO ICHIKAWA、MICHIO ISHIKAWA、YOSHIYA KOGO、SHUJI KURASHIGE、HIROSHI MIYAZAKI、HIROSHI YAMANAKA、TAKAO SAKAMOTO

  DOI：10.1248/cpb.32.995

  日期：——

  A number of 6-substituted 5, 6, 7, 8-tetrahydro-1, 6-naphthyridines designed as cyclic homologues of betahistine, 2-(2-methylaminoethyl) pyridine, were synthesized by the reduction of the corresponding 1, 6-naphthyridinium salts. The antivertigo activity of these derivatives was evaluated in terms of their ability to inhibit spontaneous nystagmus in cats. The relationships between the molecular structures of the test compounds and their antivertigo activities were investigated by a regression analysis based on the lipophilicity (π) of the substituents at the 6-position and by a conformational analysis of the compounds of interest using the modified neglect of diatomic overlap molecular orbital method. Among these compounds, the 6-allyl-and 6-cyclopropylmethyl derivatives exhibited extremely potent activity with greatly reduced hypotensive action.

  通过还原相应的 1，6-萘啶鎓盐，合成了一些 6-取代的 5，6，7，8-四氢-1，6-萘啶，它们被设计为 2-（2-甲基氨基乙基）吡啶的环状同系物。根据这些衍生物抑制猫自发性眼球震颤的能力，对其抗眩晕活性进行了评估。通过基于 6 位取代基亲油性（π）的回归分析，以及使用改进的忽略二原子重叠分子轨道法对相关化合物进行构象分析，研究了受试化合物的分子结构与其抗眩晕活性之间的关系。在这些化合物中，6-烯丙基和 6-环丙基甲基衍生物表现出极强的活性，同时大大降低了降压作用。